The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Severe acute exacerbations (AE) of idiopathic pulmonary fibrosis (IPF) are medically untreatable and often fatal within days. Recent evidence suggests autoantibodies may be involved in IPF progression. Autoantibody-mediated lung diseases are typically refractory to glucocorticoids and nonspecific medications, but frequently respond to focused autoantibody reduction treatments. We conducted a pilot trial to test the hypothesis that autoantibody-targeted therapies may also benefit AE-IPF patients. METHODS: Eleven (11) critically-ill AE-IPF patients with no evidence of conventional autoimmune diseases were treated with therapeutic plasma exchanges (TPE) and rituximab, supplemented in later cases with intravenous immunoglobulin (IVIG). Plasma anti-epithelial (HEp-2) autoantibodies and matrix metalloproteinase-7 (MMP7) were evaluated by indirect immunofluorescence and ELISA, respectively. Outcomes among the trial subjects were compared to those of 20 historical control AE-IPF patients treated with conventional glucocorticoid therapy prior to this experimental trial. RESULTS: Nine (9) trial subjects (82%) had improvements of pulmonary gas exchange after treatment, compared to one (5%) historical control. Two of the three trial subjects who relapsed after only five TPE responded again with additional TPE. The three latest subjects who responded to an augmented regimen of nine TPE plus rituximab plus IVIG have had sustained responses without relapses after 96-to-237 days. Anti-HEp-2 autoantibodies were present in trial subjects prior to therapy, and were reduced by TPE among those who responded to treatment. Conversely, plasma MMP7 levels were not systematically affected by therapy nor correlated with clinical responses. One-year survival of trial subjects was 46+15% vs. 0% among historical controls. No serious adverse events were attributable to the experimental medications. CONCLUSION: This pilot trial indicates specific treatments that reduce autoantibodies might benefit some severely-ill AE-IPF patients. These findings have potential implications regarding mechanisms of IPF progression, and justify considerations for incremental trials of autoantibody-targeted therapies in AE-IPF patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT01266317.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patients with respiratory failure due to an AE-IPF showed clinical improvement after undergoing combined plasmapheresis (which would be presumed to remove offending antibodies) and anti-CD20 therapy (170).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
BAFF, APRIL and their receptors: Structure, function and signaling
Bossen, C., & Schneider, P. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.04.006 · Cited by 521
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
Evidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testing
Solomon, D. H., Kavanaugh, A. J., Schur, P. H., & American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10561 · Cited by 510
Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Gelfand, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1009433 · Cited by 495
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381
Self-citationFranks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
Herazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325
Self-citationJacobi, A. M., Reiter, K., Mackay, M., Aranow, C., Hiepe, F., Radbruch, A., Hansen, A., Burmester, G., Diamond, B., Lipsky, P. E., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23498 · Cited by 289
DePianto, D. J., Chandriani, S., Abbas, A. R., Jia, G., N'Diaye, E. N., Caplazi, P., Kauder, S. E., Biswas, S., Karnik, S. K., Ha, C., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2013-204596 · Cited by 287
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Rituximab treatment of the anti-synthetase syndrome—a retrospective case series
Sem, M., Molberg, Ø., Lund, M. B., & Gran, J. T. (2009) · Rheumatology · doi:10.1093/rheumatology/kep157 · Cited by 218
Mechanisms of Immune Complex–Mediated Neutrophil Recruitment and Tissue Injury
Mayadas, T. N., Tsokos, G. C., & Tsuboi, N. (2009) · Circulation · doi:10.1161/circulationaha.108.771170 · Cited by 208
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008959 · Cited by 203 · cited 1×
“Given many parallels between classical autoimmune syndromes and IPF [3–21,44–46], we hypothesized specific treatments that reduce autoantibodies might also benefit AE-IPF patients.”
BackgroundSelf-citationC-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis
Vuga, L. J., Tedrow, J. R., Pandit, K. V., Tan, J., Kass, D. J., Xue, J., Chandra, D., Leader, J. K., Gibson, K. F., Kaminski, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1592oc · Cited by 197
Self-citationKahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Self-citationMarchal-Sommé, J., Uzunhan, Y., Marchand-Adam, S., Valeyre, D., Soumelis, V., Crestani, B., & Soler, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5735 · Cited by 179
Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J., Vuga, L., Tan, J., Csizmadia, E., Otterbein, L., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 161
Self-citationCellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis
Feghali-Bostwick, C. A., Tsai, C. G., Valentine, V. G., Kantrow, S., Stoner, M. W., Pilewski, J. M., Gadgil, A., George, M. P., Gibson, K. F., Choi, A. M. K., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2592 · Cited by 160
Self-citationThe Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
Brettschneider, J., Czerwoniak, A., Şenel, M., Fang, L., Kassubek, J., Pinkhardt, E. H., Lauda, F., Kapfer, T., Jesse, S., Lehmensiek, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011986 · Cited by 143
Rioja, I., Hughes, F. J., Sharp, C. H., Warnock, L. C., Montgomery, D. S., Akil, M., Wilson, A. G., Binks, M. H., & Dickson, M. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23667 · Cited by 140
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
Keir, G. J., Maher, T. M., Hansell, D. M., Denton, C. P., Ong, V. H., Singh, S., Wells, A. U., & Renzoni, E. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00163911 · Cited by 139
Rheumatoid Arthritis: A Role for Immunosenescence?
Lindström, T. M., & Robinson, W. H. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02965.x · Cited by 137
Souto‐Carneiro, M., Mahadevan, V., Takada, K., Fritsch-Stork, R. D. E., Nanki, T., Brown, M. R., Fleisher, T. A., Wilson, M., Goldbach‐Mansky, R. T., & Lipsky, P. E. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2718 · Cited by 135
Goronzy, J. J., Li, G., Yu, M., & Weyand, C. M. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.04.003 · Cited by 134
Nuovo, G. J., Hagood, J. S., Magro, C. M., Chin, N., Kapil, R., Davis, L., Marsh, C. B., & Folcik, V. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.166 · Cited by 123 · cited 1×
“[18,20] Tissue deposits of antigen-antibody (immune) complexes and activated complement are highly injurious mediators of autoantibody productions in other immunological diseases,[28] and these abnormalities are also near ubiquitous in IPF lungs.[5,12,18] Increased proportions of B-cells are differentiated in patients…”
BackgroundOrlin, J., & Berkman, E. M. (1980) · Blood · doi:10.1182/blood.v56.6.1055.1055 · Cited by 121
Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis
Taillé, C., Grootenboer-Mignot, S., Boursier, C., Michel, L., Debray, M.-P., Fagart, J., Barrientos, L., Mailleux, A., Cigna, N., Tubach, F., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0076oc · Cited by 120
Kurosu, K., Takiguchi, Y., Okada, O., Yumoto, N., Sakao, S., Tada, Y., Kasahara, Y., Tanabe, N., Tatsumi, K., Weiden, M. D., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.756 · Cited by 111
B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis
François, A., Gombault, A., Villeret, B., Alsaleh, G., Fanny, M., Gasse, P., Adam, S. M., Crestani, B., Sibilia, J., Schneider, P., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.08.003 · Cited by 109
Dillon, S. R., Harder, B., Lewis, K. B., Moore, M. D., Liu, H., Bukowski, T. R., Hamacher, N. B., Lantry, M., Maurer, M. F., Krejsa, C. M., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2959 · Cited by 107
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
Borie, R., Debray, M., Laine, C. M., Aubier, M., & Crestani, B. (2009) · European Respiratory Journal · doi:10.1183/09031936.00160908 · Cited by 103
Lee, H.-T., Shiao, Y.-M., Wu, T.-H., Chen, W., Hsu, Y., Tsai, S., & Tsai, C. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090450 · Cited by 101
Idiopathic Pulmonary Fibrosis Related to Endothelial Injury and Antiendothelial Cell Antibodies
MAGRO, C. M. J., Waldman, W. J., Knight, D. A., Allen, J. N., Nádasdy, T., Frambach, G. E., Ross, P., & Marsh, C. B. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.026 · Cited by 100
BPIFB1 Is a Lung-Specific Autoantigen Associated with Interstitial Lung Disease
Shum, A. K., Alimohammadi, M., Tan, C. L., Cheng, M., Metzger, T. C., Law, C. S., Lwin, W. W., Perheentupa, J., Bour-Jordan, H., Carel, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006998 · Cited by 95
Corsiero, E., Bombardieri, M., Manzo, A., Bugatti, S., Uguccioni, M., & Pitzalis, C. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.04.013 · Cited by 91
Vittal, R., Mickler, E. A., Fisher, A. J., Zhang, C., Rothhaar, K., Gu, H., Brown, K. M., Emtiazdjoo, A., Lott, J. M., Frye, S. B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076451 · Cited by 78
Infections and Autoimmunity: A Panorama
Pordeus, V., Szyper‐Kravitz, M., Levy, R. A., Vaz, N. M., & Shoenfeld, Y. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8048-8 · Cited by 75
Campbell, D. A., Poulter, L. W., Janossy, G., & du Bois, R. M. (1985) · Thorax · doi:10.1136/thx.40.6.405 · Cited by 72
Dobashi, N., Fujita, J., Murota, M., OHTSUKI, Y., Yamadori, I., Yoshinouchi, T., UEDA, R., Bandoh, S., Kamei, T., Nishioka, M., et al. (2000) · Lung · doi:10.1007/s004080000020 · Cited by 66
YANG, Y., FUJITA, J., BANDOH, S., OHTSUKI, Y., YAMADORI, I., YOSHINOUCHI, T., & ISHIDA, T. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01811.x · Cited by 62
The HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis
Xue, J., Gochuico, B. R., Alawad, A. S., Feghali‐Bostwick, C. A., Noth, I., Nathan, S. D., Rosen, G., Rosas, I. O., Đačić, S., Ocak, İ., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014715 · Cited by 58
Self-citationStudy of Immune Complexes in Bronchoalveolar Lavage Fluids
Dall’Aglio, P. P., Pesci, A., Bertorelli, G., Brianti, E., & Scarpa, S. (2009) · Respiration · doi:10.1159/000195495 · Cited by 48
Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis.
Ogushi, F., Tani, K., Endo, T., Tada, H., Kawano, T., Asano, T., Huang, L., Ohmoto, Y., Muraguchi, M., Moriguchi, H., et al. (2001) · PubMed · Cited by 43
Use of Combined Plasmapheresis and Immunosuppression in the Treatment of Goodpasture’s Syndrome
Erickson, S. B., Kurtz, S. B., Donadío, J. V., Holley, K. E., Wilson, C. B., & Pineda, A. A. (1979) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)19154-4 · Cited by 42
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2012) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2012.01.001 · Cited by 37
Removal kinetics of therapeutic apheresis.
Reverberi, R., & Reverberi, L. (2007) · PubMed · doi:10.2450/2007.0032-07 · Cited by 36
4. Autoimmunity, vasculitis, and autoantibodies
Lee, S. J., & Kavanaugh, A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.06.023 · Cited by 25
Wallace, W. A., & Howie, S. (2001) · The Journal of Pathology · doi:10.1002/path.916 · Cited by 21
Treatment of Autoimmune Disease: Synergy Between Plasma Exchange and Intravenous Immunoglobulins
Nydegger, U. E., & Sturzenegger, M. (2001) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2001.00343.x · Cited by 11
Treatment of Autoimmune Disease: Synergy Between Plasma Exchange and Intravenous Immunoglobulins
Nydegger, U. E., & Sturzenegger, M. (2001) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2001.00343.x · Cited by 4
Cited by
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
What's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Metadata
- Authors
- Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-17
- Volume
- 10
- Issue
- 6
- Pages
- e0127771
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4470587
- OpenAlex
- W567581979
- Cited by
- 125
- References
- 54
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 11 · 2019: 16 · 2018: 17 · 2017: 20 · 2016: 10 · 2015: 2
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-07-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- UNC Libraries
- Funders
- University of Pittsburgh
- Medical Center, University of Pittsburgh
- National Heart, Lung, and Blood Institute (HL119960, P50HL107172, R01HL119960, HL107172)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, acute exacerbation, autoantibodies, plasma exchange, rituximab, intravenous immunoglobulin, matrix metalloproteinase-7, survival, pulmonary gas exchange
- MeSH terms
- Rituximab, Aged, Aged, 80 and over, Autoantibodies, Female, Glucocorticoids, Humans, Immunologic Factors, Lung, Male, Middle Aged, Pilot Projects, Plasma Exchange, Survival Analysis, Case-Control Studies, Immunoglobulins, Intravenous, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.